Pharmacologic increase in HIF1α enhances hematopoietic stem and progenitor homing and engraftment by Speth, Jennifer M. et al.
Brief Report
HEMATOPOIESIS AND STEM CELLS
Pharmacologic increase in HIF1a enhances hematopoietic stem and
progenitor homing and engraftment
Jennifer M. Speth,1 Jonathan Hoggatt,1,2 Pratibha Singh,1 and Louis M. Pelus1
1Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN; and 2Department of Stem Cell and Regenerative
Biology, Harvard University/Harvard Stem Cell Institute, Cambridge, MA
Key Points
• dmPGE2 stabilizes the
transcription factor HIF1a in
stem and progenitor cells.
• Pharmacologic stabilization of
HIF1a increases CXCR4 and
enhances stem and progenitor
homing and engraftment.
Hematopoietic stem cell (HSC) transplantation is a lifesaving therapy for a number of
immunologic disorders. For effective transplant, HSCs must traffic from the peripheral
blood to supportive bone marrow niches. We previously showed that HSC trafficking can
be enhanced by ex vivo treatment of hematopoietic grafts with 16-16 dimethyl pros-
taglandin E2 (dmPGE2). While exploring regulatory molecules involved in dmPGE2
enhancement, we found that transiently increasing the transcription factor hypoxia-
inducible factor 1-a (HIF1a) is required for dmPGE2-enhanced CXCR4 upregulation and
enhanced migration and homing of stem and progenitor cells and that pharmacologic
manipulation of HIF1a is also capable of enhancing homing and engraftment. We also
now identify the specific hypoxia response element required for CXCR4 upregulation.
These data define a precise mechanism through which ex vivo pulse treatment with dmPGE2 enhances the function of
hematopoietic stem and progenitor cells; these data also define a role for hypoxia and HIF1a in enhancement of hematopoietic
transplantation. (Blood. 2014;123(2):203-207)
Introduction
Hematopoietic stem cell (HSC) transplantation is a curative treatment
of immunologic malignancies, inherited metabolic diseases, and
congenital immunodeﬁciencies, and is an attractive method for gene
therapy. Transplantation success is partly dictated by the quality and
number of donor cells transplanted, and is dependent on their ability to
home to bone marrow (BM) niches, self-renew and differentiate.
Some sources ofHSCs display reduced engraftment efﬁciency because
of inadequate number, and/or poor homing. Identifying strategies to
enhance homing and expansion of HSCs can improve transplant
efﬁciency, particularly when HSC number is limited. It is known that
prostaglandin E2 (PGE2) can stimulate hematopoietic stem and
progenitor cell (HSPC) proliferation.1,2 Recently, the long-acting
PGE2 analog 16-16 dimethyl PGE2 (dmPGE2) was identiﬁed in
a zebraﬁsh chemical screen as a regulator of hematopoiesis, and ex
vivo exposure to dmPGE2 was shown to increase engraftment in
murine and nonhuman primate models.3,4 This strategy has now
progressed to a phase 1 clinical trial.5 We previously demonstrated
that part of the mechanisms of action for PGE2 were the result of
increases in homing, survival, and proliferation of murine and
human HSCs.6 PGE2 enhances HSC homing primarily by increasing
CXCR4 expression on HSCs; however, the mechanism(s) whereby
PGE2 modulates CXCR4 and HSC homing has not been deﬁned.
HSCs have been reported to lie in hypoxic BM niches7-10 that
support stabilization of hypoxia-inducible factor 1 a (HIF1a) within
HSCs. HSCs that reside in hypoxic niches have greater hematopoietic-
repopulating ability,11 although recent evidence suggests that
HSCs may inherently maintain hypoxic status independently
from their speciﬁc BM localization.12 HIF1a dose-dependently
regulates HSC activity,9 and intracellular oxygenation status
plays a role in HSC quiescence and expansion.9,13,14 Given that
HIF1a and hypoxia regulate CXCR4 transcription in some
cancer cell lines15-20 and PGE2 can stabilize HIF1a in prostate
cancer cells,21-23 we hypothesized that PGE2 may increase CXCR4
and HSC engraftment through effects on HIF1a. Herein, we dem-
onstrate that PGE2 stabilizes HIF1a protein and transcriptional
activity, which is required for enhanced HSPC homing, and identify
a pharmacologic target for ex vivo enhancement of HSC function.
Materials and methods
Mice
Mice were bred in-house or were purchased from Jackson Laboratory (Bar
Harbor, ME) and maintained in the Indiana University School of Medicine
animal facility. Conditional HIF1a knockout (KO) mice were generated
by breeding HIF1aFlox/Flox and tamoxifen-Cre mice, then crossing hemi-
zygous ﬂoxed pups with homozygous HIF1aFlox/Flox mice. Resulting Cre1
HIF1aFlox/Flox mice were used. Experiments were approved by the Insti-
tutional Animal Care and Use Committee of the Indiana University
School of Medicine. Additional materials and methods are provided in
the supplemental Methods (available on the Blood Web site).
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Figure 1. PGE2 increases HIF1a protein and downstream responsive genes. (A) (Top) Representative blot of HIF1a protein 4 hours after treatment with vehicle, 1 mM of
dmPGE2, or 5 mM of DMOG. (Bottom) Densitometry analysis of HIF1a protein expression in mouse lineage
neg BMCs treated with vehicle, dmPGE2, or DMOG. Data are
expressed as X 6 standard error of the mean (SEM) percent change in protein levels over vehicle control from 3 separate experiments. (B) Expression of HIF1 responsive
genes in mouse lineageneg BMCs after treatment with dmPGE2 and DMOG as determined by quantitative reverse-transcription polymerase chain reaction. Data are X6 SEM,
N 5 3 experiments. *P , .05. (C) (Top) Dose-response blot of HIF1a protein 4 hours after treatment with vehicle or DMOG. (Bottom) Densitometry analysis of HIF1a protein
expression in mouse lineageneg BMC. (D) Dose response of CXCR4 on SKL cells treated with vehicle or DMOG. Lineageneg BMCs were treated with DMOG for 2 hours at
37°C, washed, and incubated in RPMI with 10% heat-inactivated fetal calf serum for 16 hours. CXCR4 expression on LSK-gated cells was analyzed by flow cytometry. (E) In
vitro transwell migration of murine SKL cells. One million lineageneg BMCs were treated with vehicle, dmPGE2, or DMOG. Cells were assayed for the ability to migrate to
100 ng/mL recombinant murine SDF-1 for 4 hours at 37°C. Data are expressed as X 6 SEM, N5 9. (F) BMCs from CD45.1 mice were treated with vehicle, 1 mM of dmPGE2,
or 5 mM of DMOG and 1 3 106 treated lineageneg cells transplanted into lethally irradiated CD45.2 mice. At 16 hours later, BM was analyzed for homed SKL cells. Data are
represented as X 6 SEM from 2 separate experiments (N 5 4-5 mice/group/experiment, each assayed individually). (G) Similar homing experiment with or without the
addition of AMD3100 10 minutes before transplantation. Data are represented as X 6 SEM from 2 separate experiments (N 5 4-5 mice/group/experiment, each assayed
individually) *P , .05. (H) Percent contribution (chimerism) and (I) frequency analysis for DMOG determined by Poisson statistics using LCALC software. Vehicle
P05 121 319 and DMOG P05 53 956. (J) Competitive repopulating units of DMOG and vehicle-treated cells in peripheral blood 6 months after transplant. Data are
represented as X6 SEM from 2 pooled experiments (N5 5 mice/group/experiment, each assayed individually). (K) Secondary transplant percent chimerism at 6 months after
transplant (N 5 6 mice/group each assayed individually). *P , .05.
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Figure 2. HIF1a transcriptional activity is necessary for PGE2-induced CXCR4 upregulation. (A) (Left) CXCR4 cell surface expression (X 6 SEM; N 5 3 experiments)
on HIF1b (2) and HIF1b (1) cells 24 hours after treatment with dmPGE2. CXCR4 cell surface expression was determined by flow cytometry. Data are expressed as percent
change in mean fluorescence intensity of CXCR4 over vehicle. *P , .05. (Right) CXCR4 cell surface expression (X 6 SEM; N 5 3 experiments) in HIF1b (2) and HIF1b (1)
cells 2 hours after treatment with vehicle or dmPGE2 determined by quantitative reverse-transcription polymerase chain reaction. (B) Schematic of pGL2b luciferase reporter
constructs containing various regions of the murine CXCR4 promoter. (C) In vitro Luciferase reporter assay. 293T cells were transfected with either full-length CXCR4
promoter constructs containing all HREs (Full), truncated constructs containing 1 HRE (DHRE1) or 2 HREs (DHRE2), or a mutated 1.3 kb of HRE (HRE 2 Mut). After 24 hours,
cells were split equally and treated with either vehicle or dmPGE2 for 16 hours at 37°C. Luciferase activity was measured using the Firefly Luciferase assay kit (Promega).
Data are represented as X 6 SEM from 2 separate experiments (N 5 6). *P , .05. (D) (Top) Representative blot of HIF1a protein 4 hours after treatment with vehicle,
dmPGE2, or DMOG, with or without the addition of SNP. (Bottom) Densitometry analysis of HIF1a protein expression in mouse lineage
neg BMCs treated with vehicle,
dmPGE2, or DMOG, with or without the addition of SNP. Data are expressed as X 6 standard deviation percent change in protein levels over vehicle control from 2 separate
experiments. (E) Expression of HIF1 responsive genes after treatment with vehicle or dmPGE2 with or without SNP. Data are expressed as X 6 SEM, N 5 3 experiments. (F)
(Left) In vitro transwell migration of murine SKL cells to 100 ng/mL of SDF-1. Lineageneg cells were treated with vehicle or 1 mM of dmPGE2 with or without 100 mM of SNP for
2 hours at 37°C. Data are expressed as mean 6 SEM, N 5 3 experiments. *P , .05. (Right) Representative fluorescence-activated cell sorter histogram showing CXCR4
expression on SKL cells compared with isotype control. (G) In vivo homing of HIF1a KO cells. BMCs from conditional HIF1a KO or floxed control (CD45.2) mice were treated
with vehicle or dmPGE2, and 13 10
6 treated lineageneg cells were transplanted into lethally irradiated BoyJ (CD45.1) mice. At 16 hours later, BM was analyzed for homed SKL
cells. Data are represented as X6 SEM from 1 experiment (N5 4-5 mice/group/experiment, each assayed individually). (H) CXCR4 expression (X6 SEM) on HIF1a KO and
HIF1a Floxed SKL cells after treatment with dmPGE2. N 5 3 mice/group, each assayed individually. *P , .05.
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Results and discussion
We previously demonstrated that short-term exposure to PGE2
upregulates HSPC CXCR4 and enhances their migration to stromal
cell-derived factor 1 (SDF-1) and BM homing in vivo. However, the
mechanisms whereby PGE2 modulates HSPC CXCR4 and homing
are unknown. In prostate cancer cells and renal tubular cells,21,22
PGE2 stabilizes HIF1a protein without affecting messenger RNA
(mRNA), and inhibiting PGE2 biosynthesis reduces HIF1a and
HIF-responsive genes.23 In HEK cells and in microglial cells,
HIF1a upregulates CXCR4 by interacting with hypoxia response
elements (HREs) within the CXCR4 promoter.18,19 We hypothe-
sized that the enhancing effect of PGE2 on HSPC CXCR4, migration,
and homing could result from HIF1a stabilization and enhanced
HIF1a transcriptional activity and that pharmacologic manipulation
of HIF1a may be an adjunct or alternative strategy to enhance HSC
engraftment. We ﬁrst determined whether PGE2 stabilizes HIF1a in
primary BM cells (BMCs), compared with the prolyl hydroxylase
domain inhibitor dimethyloxalyglycine (DMOG), a known HIF1a
stabilizer.24 Pulse treatment of lineageneg BMCs with 1 mM of
dmPGE2 or 5 mM of DMOG signiﬁcantly increased HIF1a protein
expression by ;35% (Figure 1A), with no effect on HIF1a mRNA
(Figure 1B). Concomitantly, mRNA levels of 2 downstream HIF1
responsive genes adrenomedullin and glucose transporter-1 were
signiﬁcantly increased after PGE2 and DMOG treatment (Figure 1B),
conﬁrming that HIF1a stabilization led to increased HIF1a tran-
scriptional activity.
Given the similar effects of dmPGE2 and DMOG on HIF1a, we
investigated if DMOG similarly affects HSPC function. Pulse
exposure of lineageneg BMC dose-dependently increased HIF1a pro-
tein expression (Figure 1C) with a concomitant dose-response
increase in CXCR4 levels on Sca-11 c-kit1 lineageneg (SKL) cells
(Figure 1D). Functionally, DMOGpulse exposure also enhanced SKL
migration to SDF-1 comparable to dmPGE2 (Figure 1E). In a congenic
in vivo homing model, treatment of BMCs with DMOG enhanced
SKL cell homing equivalent to dmPGE2 (Figure 1F). As we reported
for PGE2,
6 enhanced homing of SKL cells by DMOGwas completely
blocked by the selective CXCR4 antagonist AMD3100 (Figure 1G).
In a limiting dilution, head-to-head congenic transplant model,
DMOG treatment of BMC before transplantation signiﬁcantly in-
creased peripheral blood chimerism at 6 months after transplantation
compared with vehicle-treated cells (Figure1H), with no differences in
lineage reconstitution between recipient, vehicle, and DMOG-treated
cells (data not shown). Enhanced chimerism as a result of DMOG
treatment stemmed from a twofold increase in HSC frequency
(Figure 1I) and competitive repopulating units (Figure 1J). Enhanced
chimerism was maintained in secondary transplants (Figure 1K). That
the enhancing effects of dmPGE2 on HSPC homing and engraftment
can be duplicated by DMOG suggests that PGE2 may mediate its
effect on HSPC CXCR4 through stabilization of HIF1a.
Under normoxic conditions, HIF1a is ubiquitinated and targeted
for proteasomal degradation.25-27 In the absence of oxygen, HIF1a
is stabilized and translocated to the nucleus by HIF1b, where the
translocated HIF complex interacts with HREs within the promoter
of responsive genes.28 To further deﬁne a HIF1a requirement for
PGE2-induced CXCR4 upregulation, we used mutant mouse he-
patoma cells lacking or reconstituted with the HIF1b nuclear trans-
locator.29 In mutant hepatoma cells stably transfected with HIF1b,
dmPGE2 increased CXCR4 mRNA approximately threefold, and
CXCR4 surface expression approximately twofold, whereas dmPGE2
failed to increase CXCR4 in HIF1b (2) mutant cells (Figure 2A).
The CXCR4 promoter contains 3 potential HREs, with the HRE
located 21.3 kb from the transcriptional start site being necessary
for hypoxia-induced CXCR4 upregulation in HEK cells.18 Using
a series of luciferase CXCR4 promoter vectors containing speciﬁc
combinations of HREs (Figure 2B), a signiﬁcant increase in luciferase
activity was observed in dmPGE2-treated cells transfected with the
vector containing the 21.3 kb of HRE. However, when the 21.3 kb
of HRE was either absent (DHRE2) or mutated (HRE2 Mut), no
change in luciferase activity (Figure 2C) was observed after dmPGE2
treatment, indicating that the21.3 kb of HRE is required for CXCR4
regulation by both hypoxia and PGE2. Taken together, these data
indicate that HIF1a transcriptional activity is required for PGE2-
induced gene transcription of CXCR4 and results fromHIF1a nuclear
translocation and binding to the 21.3 kb of HRE within the
CXCR4 promoter, although we cannot rule out other regulatory
elements between HRE1 and HRE2 that may be contributing to
CXCR4 regulation in response to hypoxia.
To support the hypothesis that HIF1a is required for transcrip-
tional upregulation of CXCR4 by PGE2, we used pharmacologic and
genetic approaches to determine whether the effects of PGE2 on
increasing CXCR4 expression and migration to SDF-1 in primary
HSPCs were mediated by HIF1a stabilization. Using sodium nitro-
prusside (SNP), a compound that inhibits HIF1a protein accumula-
tion,30,31 we saw an inhibition in bothDMOGand dmPGE2-mediated
HIF1a stabilization (Figure 2D), as well as dmPGE2-mediated
upregulation of HIF-responsive genes (Figure 2E). SNP also blocked
the increase in migration to SDF-1 and CXCR4 expression, normally
seen with PGE2 (Figure 2F). Conditional deletion of HIF1a resulted
in loss of PGE2-induced enhanced HSPC homing in HIF1a KO cells
(Figure 2G), and no increase in CXCR4 expression after dmPGE2
treatment was observed (Figure 2H), further supporting the obser-
vation that HIF1a is required for PGE2-induced CXCR4 upregulation
and enhanced homing.
In summary, we provide new mechanistic insight into the effects
of PGE2 on HSC homing and engraftment and deﬁne a new ex vivo
pharmacologic strategy to enhance hematopoietic transplantation.
This ﬁnding that HIF1a stabilization by DMOG improves HSC
homing and engraftment, along with recent evidence that human
CD341 cells cultured in hypoxic conditions exhibit elevated levels
of CXCR432 and that in vivo administration of DMOG enhances
HSC recovery after total body irradiation,33 suggests several poten-
tial therapeutic strategies targeting HIF1a to improve HSC en-
graftment and repopulation.
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